Company / Shareholders' Equity
Mineralys Therapeutics, Inc. Shareholders' Equity History
FY2022-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$191.3M
FY2024
5-year range
-$52.3M / $241.2M
FY2022-FY2024
Trend
-20.7%
vs FY2023
Sector context
#154 of 213
Health Care
What the data says
At $191M, Mineralys Therapeutics, Inc.'s shareholders' equity ranks #154 of 213 in the Health Care sector. Improved from -$52M to $191M over the past 2 years.
Based on SEC 10-K filings.
$191M in FY2024.
Improved from -$52M to $191M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#154 of 213 in Health CareTop 72% of 213This company $191.3M Sector average $2.5B
▼
-92.5% below sector average
Key checks
Key Insights
- In FY2024, shareholders' equity decreased 20.7% year-over-year.
- Ranks #154 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 3.25 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $191.3M | -20.7% |
| FY2023 | $241.2M | +561.4% |
| FY2022 | -$52.3M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026